NovoCure Limited reported its financial results for the second quarter of 2026, revealing a net revenue of $183.6 million, a 16% increase from $158.8 million in the same period of 2025. For the first half of 2026, revenues reached $357.6 million, up 14% from $313.8 million year-over-year. The growth was primarily driven by an 18% increase in active patients globally, with notable contributions from international markets, which added $16.1 million to the quarterly revenue. However, the company recorded a net loss of $15.7 million for the quarter, compared to a loss of $40.1 million in the prior year, indicating a significant reduction in losses.
In terms of operational metrics, NovoCure reported a total of 5,128 active patients as of June 30, 2026, compared to 4,331 a year earlier. The company also noted that the launch of Optune Pax for pancreatic cancer contributed $1.6 million in revenue during the quarter, while Optune Lua generated $5.4 million, reflecting the ongoing adoption of its products. The company has been actively pursuing coverage policies with payers to expand access to its therapies, including a recent national reimbursement coverage policy approval in Japan for Optune Lua.
The company’s cost of revenues for the second quarter was $41.1 million, slightly down from $41.5 million in the previous year, attributed to a $4.9 million tariff refund and improved manufacturing efficiencies. Gross profit for the quarter was $142.5 million, resulting in a gross margin of 78%, up from 74% in the prior year. Operating expenses totaled $153.0 million, a decrease from $156.9 million, with research and development costs slightly down and sales and marketing expenses increasing due to the launch of new products.
NovoCure's balance sheet as of June 30, 2026, showed total assets of $795.2 million, a decrease from $804.3 million at the end of 2025. The company had cash, cash equivalents, and short-term investments totaling $440.6 million, down from $447.7 million at year-end 2025. The company continues to manage its capital resources carefully, anticipating that operating expenses may outpace gross profit as it expands into new indications. Looking ahead, NovoCure remains focused on driving commercial adoption of its products and exploring additional clinical trials to enhance its market position in oncology.
About NovoCure Ltd
NovoCure Limited is a global oncology company specializing in Tumor Treating Fields (TTFields) technology, which uses electric fields to disrupt cancer cell division. Its core products, Optune Gio and Optune Lua, are medical devices approved for treating glioblastoma, non-small cell lung cancer, and mesothelioma. The company markets its therapies worldwide, emphasizing clinical research, regulatory compliance, and innovative device development to extend survival and improve quality of life for cancer patients.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.